cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5519/qd.hkp4poh6
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (157 records)
DOI: 10.5167/uzh-284393
title: Diplophyllum albicans (L.) Dumort.
DOI: 10.18419/darus-5706/7
title: Figure_4_11_Cartesian_mixedexponents.mp4
DOI: 10.18419/darus-5706/9
title: Figure_4_11_polar_quadratic.mp4
DOI: 10.18419/darus-5706/4
title: Figure_4_6_trailer_quadratic.mp4
DOI: 10.18419/darus-5706/6
title: Figure_4_8_car_quadratic.mp4
DOI: 10.18419/darus-5706/1
title: Figure_4_4_diffdrive_mixedexponents.mp4
DOI: 10.18419/darus-5706/2
title: Figure_4_4_diffdrive_quadratic.mp4
DOI: 10.18419/darus-5706/3
title: Figure_4_6_trailer_mixedexponents.mp4
DOI: 10.18419/darus-5706/5
title: Figure_4_8_car_mixedexponents.mp4
DOI: 10.18419/darus-5706/8
title: Figure_4_11_polar_mixedexponents.mp4
DOI: 10.18419/darus-5706/12
title: Figure_5_7_formation_polar_mixedexponents.mp4
DOI: 10.18419/darus-5706/11
title: Figure_5_4_formation_quadratic.mp4
DOI: 10.18419/darus-5706/13
title: Figure_5_7_formation_polar_quadratic.mp4
DOI: 10.18419/darus-5706/10
title: Figure_5_4_formation_mixedexponents.mp4
DOI: 10.15468/dl.w2wvk7
title: Occurrence Download

description: A dataset containing 1769 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (Norway, United Kingdom of Great Britain and Northern Ireland, Faroe Islands, Sweden)",
 "TaxonKey is Anastrophyllum donnianum"
 ]
}

 The dataset includes 1769 records from 51 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011680-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.sgecc3
title: Occurrence Download

description: A dataset containing 92 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Tetracera daemeliana",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 92 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011681-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.gqfr57
title: Occurrence Download

description: A dataset containing 5 species occurrences available in GBIF matching the query:
{
 "GbifId" : [
 "is one of (1318310769, 614799960, 543500926, 476552114, 1837124770)"
 ]
}

 The dataset includes 5 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011682-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.sfzsee
title: Occurrence Download

description: A dataset containing 1410425 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Thalasseus maximus"
 ]
}

 The dataset includes 1410425 records from 311 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0011625-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30315445
title: Supplementary Material for: Epidemiology of Neuroendocrine Neoplasia worldwide – A Review of the Literature (2012-2022)

description: Background 
The incidence of NENs has been rising globally; However, epidemiological studies on NENs often lack comprehensive geographical comparisons, with limited reporting on demographic variations, risk factors, and tumour site-specific trends. 

Summary
This review examines the global epidemiological trends in NENs, focusing on incidence, demographic variations, risk factors, and survival outcomes across tumour sites. A literature search was conducted using PubMed, Medline, and Embase, identifying 74 eligible epidemiology-focused studies on adult NEN populations published between 2012 and October 13, 2022. Results indicate a rising incidence of NENs across multiple sites, with significant regional and demographic variations. Gastrointestinal NENs are the most prevalent, with rectal NENs experiencing the highest increase. Gastric NENs are more common in Asian countries, while appendiceal NENs are predominantly found in younger Caucasian females. Pancreatic NENs exhibit racial disparities, with Black patients diagnosed at younger ages and facing socioeconomic barriers to care. Lung NEN incidence is rising, except for small cell lung cancer, which is declining due to reduced smoking rates. Survival outcomes vary by site, with rectal and appendiceal NENs having better prognoses and gastric and colonic NENs having worse survival rates. Across all sites, advancing age is linked to poorer survival, while females generally have better outcomes. Common modifiable risk factors include obesity, type 2 diabetes, smoking, alcohol consumption, and metabolic syndrome.

Key Messages
This review provides a comprehensive global perspective on NEN epidemiology, allowing healthcare providers to identify high-risk populations to inform screening strategies and address modifiable risk factors to help mitigate the increasing incidence and improve patient outcomes worldwide.
DOI: 10.6084/m9.figshare.30315445.v1
title: Supplementary Material for: Epidemiology of Neuroendocrine Neoplasia worldwide – A Review of the Literature (2012-2022)

description: Background 
The incidence of NENs has been rising globally; However, epidemiological studies on NENs often lack comprehensive geographical comparisons, with limited reporting on demographic variations, risk factors, and tumour site-specific trends. 

Summary
This review examines the global epidemiological trends in NENs, focusing on incidence, demographic variations, risk factors, and survival outcomes across tumour sites. A literature search was conducted using PubMed, Medline, and Embase, identifying 74 eligible epidemiology-focused studies on adult NEN populations published between 2012 and October 13, 2022. Results indicate a rising incidence of NENs across multiple sites, with significant regional and demographic variations. Gastrointestinal NENs are the most prevalent, with rectal NENs experiencing the highest increase. Gastric NENs are more common in Asian countries, while appendiceal NENs are predominantly found in younger Caucasian females. Pancreatic NENs exhibit racial disparities, with Black patients diagnosed at younger ages and facing socioeconomic barriers to care. Lung NEN incidence is rising, except for small cell lung cancer, which is declining due to reduced smoking rates. Survival outcomes vary by site, with rectal and appendiceal NENs having better prognoses and gastric and colonic NENs having worse survival rates. Across all sites, advancing age is linked to poorer survival, while females generally have better outcomes. Common modifiable risk factors include obesity, type 2 diabetes, smoking, alcohol consumption, and metabolic syndrome.

Key Messages
This review provides a comprehensive global perspective on NEN epidemiology, allowing healthcare providers to identify high-risk populations to inform screening strategies and address modifiable risk factors to help mitigate the increasing incidence and improve patient outcomes worldwide.
DOI: 10.15468/dl.ayxs6w
title: Occurrence Download

description: A dataset containing 51883 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Paulownia tomentosa)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 51883 records from 414 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0064091-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30315448
title: Supplementary Material for: Overall survival in metastatic breast cancer patients: Real world data from 1000 patients treated at the NCT Heidelberg between 2014 and 2022

description: Introduction: In recent years, targeted therapeutic options for metastatic breast cancer (mBC) have improved significantly. In this analysis, we evaluated overall survival (OS) data of a prospectively documented cohort of 1000 patients with mBC treated at the NCT Heidelberg from 2014 to 2022. 
Patients and methods: Clinical data were prospectively collected and documented in the Prospective Academic Translational Research PRAEGNANT Network. OS was analyzed according to molecular subtype and line of therapy at study entry. We further evaluated the clinical characteristics associated with long-term (&gt;5 years) and short-term (&lt; 1 year) survival.
Results: The median age at first diagnosis of metastasis was 57 years. Fourteen % of patients presented with triple-negative, 20% with HER2-positive, and 66% with hormone receptor-positive, HER2-negative mBC. Median OS was 31.7 month. The longest median OS was observed in patients with HER2-positive and luminal A-like mBC (42 and 39 months, respectively). Patients with luminal B-like and triple-negative mBC showed significantly shorter OS (21 and 14 months, respectively). In univariable Cox regression analysis significantly shorter OS was associated with higher tumor grade, negative estrogen receptor (ER)-, progesterone receptor (PR)-, and HER2 status, triple-negative molecular subtype, use of (neo)adjuvant chemotherapy and later line of therapy at study entry. Multivariable Cox regression analysis revealed that higher tumor grade, negative ER and HER2 status, triple-negative or luminal B-like tumor biology, and study entry during later lines of therapy were the main risk factors for shorter OS. At 5 years follow up 17% of patients were still alive. Long-term survivors (&gt;5 years) were more frequently ER-, PR-, and HER2-positive, received less often (neo)adjuvant chemotherapy, and had a longer disease-free interval.
Conclusion: This prospective real-world analysis of 1000 mBC patients demonstrated significant OS differences, emphasizing the importance of personalized treatment approaches.
DOI: 10.6084/m9.figshare.30315448.v1
title: Supplementary Material for: Overall survival in metastatic breast cancer patients: Real world data from 1000 patients treated at the NCT Heidelberg between 2014 and 2022

description: Introduction: In recent years, targeted therapeutic options for metastatic breast cancer (mBC) have improved significantly. In this analysis, we evaluated overall survival (OS) data of a prospectively documented cohort of 1000 patients with mBC treated at the NCT Heidelberg from 2014 to 2022. 
Patients and methods: Clinical data were prospectively collected and documented in the Prospective Academic Translational Research PRAEGNANT Network. OS was analyzed according to molecular subtype and line of therapy at study entry. We further evaluated the clinical characteristics associated with long-term (&gt;5 years) and short-term (&lt; 1 year) survival.
Results: The median age at first diagnosis of metastasis was 57 years. Fourteen % of patients presented with triple-negative, 20% with HER2-positive, and 66% with hormone receptor-positive, HER2-negative mBC. Median OS was 31.7 month. The longest median OS was observed in patients with HER2-positive and luminal A-like mBC (42 and 39 months, respectively). Patients with luminal B-like and triple-negative mBC showed significantly shorter OS (21 and 14 months, respectively). In univariable Cox regression analysis significantly shorter OS was associated with higher tumor grade, negative estrogen receptor (ER)-, progesterone receptor (PR)-, and HER2 status, triple-negative molecular subtype, use of (neo)adjuvant chemotherapy and later line of therapy at study entry. Multivariable Cox regression analysis revealed that higher tumor grade, negative ER and HER2 status, triple-negative or luminal B-like tumor biology, and study entry during later lines of therapy were the main risk factors for shorter OS. At 5 years follow up 17% of patients were still alive. Long-term survivors (&gt;5 years) were more frequently ER-, PR-, and HER2-positive, received less often (neo)adjuvant chemotherapy, and had a longer disease-free interval.
Conclusion: This prospective real-world analysis of 1000 mBC patients demonstrated significant OS differences, emphasizing the importance of personalized treatment approaches.
DOI: 10.34810/data1735
title: Origin, destination, and computational power analysis of reused/recycled ICT devices in the Pangea eReuse Circuit

description: This dataset captures detailed information from the Pangea circuit of eReuse, launched in 2016 to manage discarded ICT devices from the Barcelona City Council and various public and private institutions. It comprises a sample of 1,616 ICT devices, each assigned a condition score and traced using eReuse software based on the digital passport concept. These devices were donated by 41 entities (36 private and 5 public), refurbished by three reuse centres, and subsequently distributed to 101 intermediary organisations.
description: eReuse has developed two tools on which the Dataset is based. Firstly, the Workbench, which is a tool for extracting details about the device's hardware, and testing and wiping device hard disks, is run via a bootable USB stick. The details generated by Workbench are sent immediately to the second tool, the Devicehub. The DeviceHub is a cloud-based device inventory and management system, through which reuse centres manage changes in device lifecycles, exports data wipe certificates, conformity compliance, and other useful documentation. The data has been generated at the time of arrival of electronic devices, after first use to three reuse centres federated to eReuse. To create the data set, the records have been anonymised and exported from the DeviceHub from 2016 until 2021.
description: https://github.com/eReuse/, null
DOI: 10.6084/m9.figshare.30315451
title: Supplementary Material for: Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report

description: Background: Thanatophoric dysplasia type 1 (TD1) is the most severe form of FGFR3-related skeletal dysplasia, with high perinatal mortality and no approved pharmacologic therapies. Vosoritide, a C-type natriuretic peptide analogue that counteracts FGFR3 overactivation, improves growth in achondroplasia, but its effects in TD1 remains unexplored.

Methods: We report the response to vosoritide therapy in a 9-year-old girl with genetically confirmed TD1 (c.2420G&gt;T). Vosoritide was initiated at a dose of 15 µg/kg/day subcutaneously, and increased to 30 µg/kg/day after 16 months. Growth velocity, anthropometry, pulmonary function, densitometry and safety were assessed longitudinally over 28 months.

Results: At baseline, height was 78.6 cm (−10.9 SDS) and annual growth velocity (AGV) 1.6 cm/year (−4.7 SDS). After 28 months, height increased by +1.3 SDS and AGV by +2.0 cm/year (+3 SDS from baseline). Lung vital capacity improved by 65%. Serial MRI demonstrated persistent severe foramen magnum stenosis without radiological progression. Adverse events were limited to transient injection‑site reactions and mild vasovagal episodes; no major safety concerns emerged.

Conclusions: Vosoritide was well tolerated and improved growth velocity and lung function in this long‑term TD1 survivor, suggesting therapeutic potential even in severe FGFR3 overactivation. Given TD1’s rarity, larger studies and further off‑label experience are essential to validate these findings.
DOI: 10.6084/m9.figshare.30315451.v1
title: Supplementary Material for: Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report

description: Background: Thanatophoric dysplasia type 1 (TD1) is the most severe form of FGFR3-related skeletal dysplasia, with high perinatal mortality and no approved pharmacologic therapies. Vosoritide, a C-type natriuretic peptide analogue that counteracts FGFR3 overactivation, improves growth in achondroplasia, but its effects in TD1 remains unexplored.

Methods: We report the response to vosoritide therapy in a 9-year-old girl with genetically confirmed TD1 (c.2420G&gt;T). Vosoritide was initiated at a dose of 15 µg/kg/day subcutaneously, and increased to 30 µg/kg/day after 16 months. Growth velocity, anthropometry, pulmonary function, densitometry and safety were assessed longitudinally over 28 months.

Results: At baseline, height was 78.6 cm (−10.9 SDS) and annual growth velocity (AGV) 1.6 cm/year (−4.7 SDS). After 28 months, height increased by +1.3 SDS and AGV by +2.0 cm/year (+3 SDS from baseline). Lung vital capacity improved by 65%. Serial MRI demonstrated persistent severe foramen magnum stenosis without radiological progression. Adverse events were limited to transient injection‑site reactions and mild vasovagal episodes; no major safety concerns emerged.

Conclusions: Vosoritide was well tolerated and improved growth velocity and lung function in this long‑term TD1 survivor, suggesting therapeutic potential even in severe FGFR3 overactivation. Given TD1’s rarity, larger studies and further off‑label experience are essential to validate these findings.
DOI: 10.6084/m9.figshare.30315454
title: Supplementary Material for: WHOverlap Multicenter Study: Dissecting the Insufficient/Inadequate/Non-Diagnostic Category and Its Overlap with the Benign Category in the WHO Reporting System for Lung Cytology

description: Introduction:
Distinguishing between Non-Diagnostic (ND) and Benign (B) categories in lung cytopathology remains clinically challenging, especially given the significant overlap and the high risk of malignancy (ROM) often reported for ND cases. The 2022 WHO Reporting System for Lung Cytology addresses these issues but acknowledges that ND may carry up to a 60% ROM. We conducted a large, multicenter study to clarify the ND–B boundary and evaluate how radiologic findings influence ROM.
Methods:
From 12 institutions, 363 consecutive lung cytopathology cases categorized as Insufficient/Inadequate/Non-Diagnostic (I/I/ND) or Benign with histopathological follow-up were analyzed. The locally categorized cytopathological cases were subclassified centrally into: ND with insufficient cellularity (IS-C), artefactual/sample preparation error (IS-P), non-representative (NR1: no suspicious lesion; NR2: suspicious lesion); and B (B1: benign cells, no suspicious lesion; B2: benign cells, suspicious lesion). ROM was defined as the percentage of histologically confirmed malignancies in each group.
Results:
Overall, 60.6% (220/363) of cases were confirmed as malignant on histopathological evaluation. Within the ND category (n = 149), 70.5% (105/149) were malignant, exceeding the malignancy risk range estimated by the WHO system (40–60%). In comparison, the ROM for cases classified as Benign (n = 214) was 53.7% (115/214), which is consistent with the WHO system reference range.
Notably, when ND or Benign cytopathology coincided with suspicious imaging findings (NR2 (n=57) or B2 (n=124)), the ROM exceeded 75% (134/181).
These results indicate that subclassification based on imaging findings provides a more refined estimation of malignancy risk. Cases with benign cytopathology may still carry a high likelihood of malignancy when imaging features are suspicious, reinforcing the importance of integrated diagnostic evaluation. 
Conclusions:
These findings demonstrate that imaging correlation is critical for accurate risk assessment in the overlap between the ND and Benign cytopathology categories. Subclassification of ND and B cases based on imaging features and consistent reporting of ROM can help identify patients who may benefit from repeat sampling or further diagnostic evaluation. This approach has the potential to enhance diagnostic accuracy and improve clinical decision-making.
DOI: 10.6084/m9.figshare.30315454.v1
title: Supplementary Material for: WHOverlap Multicenter Study: Dissecting the Insufficient/Inadequate/Non-Diagnostic Category and Its Overlap with the Benign Category in the WHO Reporting System for Lung Cytology

description: Introduction:
Distinguishing between Non-Diagnostic (ND) and Benign (B) categories in lung cytopathology remains clinically challenging, especially given the significant overlap and the high risk of malignancy (ROM) often reported for ND cases. The 2022 WHO Reporting System for Lung Cytology addresses these issues but acknowledges that ND may carry up to a 60% ROM. We conducted a large, multicenter study to clarify the ND–B boundary and evaluate how radiologic findings influence ROM.
Methods:
From 12 institutions, 363 consecutive lung cytopathology cases categorized as Insufficient/Inadequate/Non-Diagnostic (I/I/ND) or Benign with histopathological follow-up were analyzed. The locally categorized cytopathological cases were subclassified centrally into: ND with insufficient cellularity (IS-C), artefactual/sample preparation error (IS-P), non-representative (NR1: no suspicious lesion; NR2: suspicious lesion); and B (B1: benign cells, no suspicious lesion; B2: benign cells, suspicious lesion). ROM was defined as the percentage of histologically confirmed malignancies in each group.
Results:
Overall, 60.6% (220/363) of cases were confirmed as malignant on histopathological evaluation. Within the ND category (n = 149), 70.5% (105/149) were malignant, exceeding the malignancy risk range estimated by the WHO system (40–60%). In comparison, the ROM for cases classified as Benign (n = 214) was 53.7% (115/214), which is consistent with the WHO system reference range.
Notably, when ND or Benign cytopathology coincided with suspicious imaging findings (NR2 (n=57) or B2 (n=124)), the ROM exceeded 75% (134/181).
These results indicate that subclassification based on imaging findings provides a more refined estimation of malignancy risk. Cases with benign cytopathology may still carry a high likelihood of malignancy when imaging features are suspicious, reinforcing the importance of integrated diagnostic evaluation. 
Conclusions:
These findings demonstrate that imaging correlation is critical for accurate risk assessment in the overlap between the ND and Benign cytopathology categories. Subclassification of ND and B cases based on imaging features and consistent reporting of ROM can help identify patients who may benefit from repeat sampling or further diagnostic evaluation. This approach has the potential to enhance diagnostic accuracy and improve clinical decision-making.
DOI: 10.15468/dl.47w8zd
title: Occurrence Download

description: A dataset containing 1424 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Poecilia vivipara",
 "HasCoordinate is true"
 ]
}

 The dataset includes 1424 records from 51 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0064119-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pnvnhf
title: Occurrence Download

description: A dataset containing 27 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Valerianella carinata",
 "Country is United States of America",
 "HasCoordinate is true"
 ]
}

 The dataset includes 27 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0064120-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17909/xzh5-zf02
title: Data from paper "JWST COMPASS: Insights into the Systematic Noise Properties of NIRSpec/G395H From a Uniform Reanalysis of Seven Transmission Spectra"

description: Data analyzed in the referenced paper.